SCHEDULE: Emerald Bioventures Increases Stake in Galera Therapeutics

Emerald Bioventures, LLC and Timothy Opler have increased their beneficial ownership in Galera Therapeutics to 30.2% following a mandatory conversion of Series B Preferred Stock.

Summary

• Emerald Bioventures, LLC and Timothy Opler filed an amendment to their Schedule 13D regarding Galera Therapeutics, Inc.
• On May 15, 2026, 20,813.8186192892 shares of Series B Non-Voting Convertible Preferred Stock held by Emerald were converted into 20,813,818 shares of Common Stock.
• The reporting persons now beneficially own 61,029,978 shares of Common Stock.
• This ownership represents approximately 30.2% of the total outstanding shares of Galera Therapeutics, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update reflecting the execution of previously agreed-upon contractual terms regarding equity conversion.

Positives

• The conversion of preferred stock into common stock simplifies the capital structure of the issuer.
• The reporting persons maintain a significant 30.2% stake, indicating continued commitment to the company.

Negatives

• The conversion results in significant dilution for existing common shareholders due to the issuance of over 20 million new shares.

Risks

• Concentration of ownership by a single entity (30.2%) may influence corporate decision-making and voting outcomes.
• Potential for future market volatility as a large block of shares has been converted and is now part of the common stock float.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the company's operations, but confirms the completion of the mandatory conversion of all Series B Preferred Stock held by the reporting persons.

Management Comments

• The reporting persons certify that the information set forth in the statement is true, complete, and correct.

Industry Context

StockSavvy.ai notes that mandatory conversions of preferred stock are common in biotech financing to clean up balance sheets and simplify equity structures, often signaling a transition toward more standard capital structures as companies reach clinical or commercial milestones.

Comparison to Industry Standards

• The 30.2% ownership stake is consistent with significant venture capital or private equity involvement in small-cap biotechnology firms.
• The use of mandatory conversion clauses is a standard mechanism in private placement agreements for biotech companies to manage dilution and capital requirements.

Stakeholder Impact

• Existing shareholders face dilution due to the issuance of 20,813,818 new common shares.
• The conversion eliminates the liquidation preference or other rights associated with the Series B Preferred Stock.

Next Steps

• No further specific actions or milestones were disclosed in this filing.

Key Dates

Keywords

Galera Therapeutics, Emerald Bioventures, Schedule 13D, Mandatory Conversion, Preferred Stock, Beneficial Ownership